Compass Therapeutics Inc. (CMPX) is scheduled to host a webcast on Tuesday, April 1, 2025, at 8:00 AM ET to review top-line clinical data from its ongoing COMPANION-002 clinical trial.
COMPANION-002 is a phase II/III trial evaluating the company's lead drug candidate Tovecimig plus paclitaxel against paclitaxel alone in patients with previously treated, unresectable advanced Metastatic or Recurrent Biliary Tract Cancers. This study completed enrollment of the planned 150 patients last August.
For comments and feedback contact: editorial@rttnews.com
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.